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Abstract
Background. The aim of the study was to investigate the
antihypertensive effects of angiotensin II type-1 receptor
blocker, losartan, and its potential in slowing down re-
nal disease progression in spontaneously hypertensive rats
(SHR) with adriamycin (ADR) nephropathy.
Methods. Six-month-old female SHR were randomly se-
lected in six groups. Two control groups (SH6, SH12) re-
ceived vehicle. Groups ADR6, ADR+LOS6 and ADR12,
and ADR+LOS12 received ADR (2 mg/kg/b.w. i.v.) twice
in a 3-week interval. Group ADR+LOS6 received losar-
tan (10 mg/kg/b.w./day by gavages) for 6 weeks and group
ADR+LOS12 for 12 weeks after second injection of ADR.
Animals were killed after 6 or 12 weeks, respectively.
Haemodynamic measurements were performed on anaes-
thetized animals, blood and urine samples were taken for
biochemical analysis and the left kidney was processed for
morphological studies.
Results. Short-term losartan treatment, besides antihyper-
tensive effect, improved glomerular filtration rate and ame-
liorated glomerulosclerosis resulting in decreased protein-
uria. Prolonged treatment with losartan showed further
reduction of glomerulosclerosis associated with reduced
progression of tubular atrophy and interstitial fibrosis, thus
preventing heavy proteinuria and chronic renal failure.
Losartan reduced uraemia and increased urea clearance in
advanced ADR nephropathy in SHR. Histological exami-
nation showed that losartan could prevent tubular atrophy,
interstitial infiltration and fibrosis in ADR nephropathy.
Conclusion. Losartan reduces the rate of progression of
ADR-induced focal segmental glomerulosclerosis to end-
stage renal disease in SHR.
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Introduction
Hypertension manifested with sustained high blood pres-
sure has been known as a major risk factor of many car-
diovascular pathophysiological conditions including arte-
riosclerosis, stroke, heart failure, coronary artery disease
and progressive renal damage [1]. Spontaneously hyper-
tensive rats (SHR) develop kidney damage in advanced age
[2] similar to nephropathy in patients with essential hyper-
tension [3].
On the other hand, focal segmental glomerulosclerosis
(FSGS) is characterized by nephrotic range proteinuria and
progressive renal failure in humans, like in experimental
models with similar glomerular lesions [4].
Adriamycin (ADR), doxorubicin hydrochloride, is a
highly potent antineoplastic agent that induces cell killing
by causing a variety of biochemical alterations [5]. Its ad-
ministration into rats results in heavy proteinuria accompa-
nied by glomerular sclerosis and tubulointerstitial damage
similar to the morphological picture of FSGS in humans
[6,7]. Intensive proteinuria associated with focal loss of
podocyte foot processes, swelling and vacuolization of ep-
ithelial and mesangial cells are landmarks of early stage
of ADR nephrotoxicity, while focal segmental glomeru-
lar sclerosis or even global sclerosis, tubular atrophy and
interstitial fibrosis are characteristics of late-stage ADR
nephropathy [8]. The degree of renal toxicity is a function
of the cumulative dose of ADR [5]. Its metabolism results
in reactive oxygen species formation, indicating their role
in the course of ADR-induced nephropathy [9].
Angiotensin II (ANG II) plays an important role in the
progression of chronic renal failure (CRF) [10]. Studies in
various human diseases and animal models have shown that
angiotensin I converting enzyme inhibitors (ACEI) are su-
perior to other antihypertensive drugs in protecting kidney
against progressive deterioration, even in conditions with-
out systemic hypertension, suggesting that ANG II also
has non-haemodynamic effects on progressive renal dis-
ease [11] such as growth regulation, immunomodulation,
matrix interaction and fibrogenesis [10]. In the previous
study from our laboratory, we found that ACEI, captopril,
normalized systolic blood pressure (SBP) and preserved
C© The Author [2008]. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved.
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glomerular and interstitial structure and function, without
changes in tubular and renal blood vessel structure, and
therefore failed to reduce CRF [12]. Other authors found
controversial evidence for the beneficial effects of com-
bined therapy with ACEI and ANG II AT-1 receptor an-
tagonists on the course of nephrotic proteinuria in differ-
ent experimental models and humans [13]. The observed
reduction of proteinuria induced by co-treatment was at-
tributed to the blockade of ANG II synthesized in the path-
ways including non-ACE conversion. In addition, it is well
known that ANG II is synthesized and released locally in the
kidney.
Since there was no reduction of renal disease progres-
sion in SHR with ADR nephropathy after ACE inhibition,
we decided to perform the same experimental design with
ANG II AT-1 receptor antagonist, losartan. Thus, the aim
of the present study was to examine short-term (6 weeks)
and long-term (12 weeks) effects of losartan on blood pres-
sure regulation, renal haemodynamics, kidney function and
structure, and the ability of this antihypertensive agent to




The SHR used in this study were bred at the Institute for
Medical Research, Belgrade, Serbia, and they were de-
scendants of breeders originally obtained through Taconic
Farms, Germantown, NY, USA.
Six-month-old female SHR, weighing about 200 g, were
examined for control values of SBP by an indirect method
using a tail-cuff, pneumatic pulse detector and the direct
recorder (Physiograph Four, Narco Bio-System, Houston,
TX, USA). After assuring that all animals were hyperten-
sive, we divided them randomly into six groups. Two control
SHR groups (SH6 and SH12) drank tap water throughout the
experiment and they were killed after 6 or 12 weeks, respec-
tively. Four groups of SHR received ADR twice [2 mg/kg of
body weight (b.w.) intravenously through the femoral vein
during anaesthesia with 35 mg/kg sodium pentobarbital]
with an interval of 3 weeks and they were killed after 6 or
12 weeks. The first two of these four groups (ADR6 and
ADR12) received vehicle in addition to ADR. After the sec-
ond injection of ADR, the two other groups (ADR+LOS6
and ADR+LOS12) were treated with losartan (LOS, DUP
153, Du Pont, Wilmington, DE, USA, 10 mg/kg b.w./day
by gavages) during the next 6 or 12 weeks of the experi-
ment. Animals were kept under appropriate conditions, fed
with standard laboratory chow for experimental animals
(Vetrerinarski zavod, Subotica, Serbia) and supplied by wa-
ter without restriction.
All experiments were done according to the local guide-
lines for animal research and principles of the European
Convention for the Protection of Vertebrate Animals Used
for Experimental and Other Purposes (Official Daily N. L
358/1-358/6, 18 December 1986). They were also approved
by our institutional ethic committee.
Measurements
Before direct haemodynamic measurements, rats were
weighed and placed in individual metabolic cages and urine
was collected in the next 24 h for biochemical analysis.
Haemodynamic measurements
Direct haemodynamic measurements were performed in
anaesthetized (35 mg/kg sodium pentobarbital, intraperi-
toneally) rats, after urine collection. Systolic and diastolic
arterial pressure (SAP, DAP) were measured through a
femoral artery catheter (PE-50, Clay-Adams Parsippany,
NY, USA) connected to a low-volume displacement trans-
ducer (P23 Db, Statham, Oxnard, CA, USA) and the direct
writing recorder (Physiograph Four, Nacro Bio System Inc.,
Houston, TX, USA), while mean arterial pressure (MAP)
was obtained by electronic integration. For renal haemody-
namic measurements, the renal artery was gently separated
from the surrounding tissue, and the ultrasonic flow probe
1RB (internal diameter 1 mm) was placed around the re-
nal artery. Renal blood flow (RBF) was recorded by the
Transonic T106 Small Animal Flowmeter (Transonic Sys-
tem Inc., Ithaca, NY, USA), and renal vascular resistance
(RVR) was calculated according to the standard formula,
normalized to body weight, and expressed as mmHg ×
min × kg/ml.
Biochemical measurements
At the end of the study, all rats were killed and blood sam-
ples were taken for determination of creatinine, urea
and protein concentrations. Lithium-heparin (Li-heparin,
Sigma, USA) was used as an anticoagulant. Twenty-four-
hour urine samples for determination of urinary flow were
collected in graduated cylinders with an accuracy of 0.1 ml.
These urine samples also were used for measuring creati-
nine, urea and protein concentrations. Plasma and urine
creatinine was measured by the Jaffe reaction and plasma
and urine urea by the urease reaction. Protein concentra-
tion in plasma and urine were determined by commercial
kit Randox (Crumlin, Antrim, UK). We have used spec-
trophotometer for all analysis (Cobas Mira, Roche, Elitech
Diagnostic). A standard formula was used to calculate en-
dogenous creatinine clearance and urea clearance and pro-
tein excretion. The water reabsorption rate was calculated
according to Kusaka et al. [14].
Histological examination
Left kidney was excised, dissected longitudinally and fixed
in 10% buffered formalin solution. Renal tissue samples
were dehydrated in alcohol, blocked in paraffin wax, cut
into 5-µm slices and stained by haematoxilin & eosin
(H&E) and periodic acid Schiff (PAS) reaction for light
microscopy observation.
The severity of histological changes was estimated ac-
cording to renal scarring. Sclerotic changes in glomeruli
were graded as follows: 0 normal glomeruli, 1+ slight seg-
mental changes in small number of glomeruli, 2+ segmen-
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sclerosis. Tubular dilatation with luminal PAS positive ma-
terial and atrophy of tubular epithelium as well as interstitial
infiltration and interstitial fibrosis were graded from 0 to
3+, according to extension of changes. Vascular injury was
graded as follows: 0 normal vessels, 1+ slight vacuolization
of media, 2+ hyperplasia of smooth muscle cells and 3+
PAS positive necrosis. The sum of these changes represents
the histopathological (HP) score for comparison between
treated and control groups.
Statistical analysis
The data are given as mean ± SEM. One-way analy-
sis of variance (ANOVA) was used for multiple compar-
isons between experimental groups. Newman–Keuls and
Duncan tests were performed as post hoc multiple com-




Six weeks after second injection of ADR, no difference in
the body weight was found between experimental groups
(Table 1). After 12 weeks, control SHR and SHR that re-
ceived losartan after ADR gained body weight compared
to respective groups at Week 6 and compared to ADR12,
while rats from the ADR group stagnated in body weight
during the experiment (Table 1).
Haemodynamic parameters
Directly measured SAP, DAP and MAP in all experimental
animals are shown in Table 2, while renal haemodynamics
(RBF and RVR) are presented as clustered column val-
ues across the categories obtained after 6 and 12 weeks of
treatment in Figure 1. With regard to SAP, DAP and MAP,
there were no differences between control SHR and SHR
that received ADR. SAP and MAP were significantly de-
creased in the group with 6 weeks’ losartan administration
in comparison to the control group and ADR alone.
Haemodynamic parameters obtained from the renal
artery pointed out that ADR led to remarkable reduction of
RBF at late stage of ADR nephropathy, and thereafter RVR
was significantly increased. Long-term losartan treatment
reduced SAP only, without effects on DAP and MAP. Six
weeks’ application of AT-1 receptor antagonist, losartan,
resulted in mild augmentation of RBF with a mild decrease
of RVR. However, 12 weeks’ losartan treatment induced an
increase of RBF by 59.56% and a statistically significant
decrease of RVR.
Biochemical parameters
Plasma creatinine (Pcr) and plasma urea (Pu) levels, urine
flow (Uf) and water reabsorption (Wr) are given in Table
1. The plasma creatinine level remained unchanged in all
SHR after 6 and 12 weeks of experiment, while urinary cre-
atinine dropped significantly in ADR-treated groups (SH6
versus ADR6: 7.93 ± 0.52 versus 5.29 ± 0.44 mmol/l, P <
0.01; and SH12 versus ADR12: 6.36 ± 0.58 versus 3.66 ±
0.6 mmol/l, P < 0.01). At the early stage of ADR nephropa-
thy, we found no difference in the glomerular filtration
rate (GFR) estimated by clearance of endogenous creati-
nine (ADR6 versus SH6: Figure 2). However, the GFR was
markedly elevated after 6 weeks of losartan treatment, as
compared to SHR without ADR.
The plasma urea concentration in ADR6 (Table 1) and the
urinary urea concentration in SHR killed 6 and 12 weeks
after the second ADR injection were significantly de-
creased compared to control SHR (P < 0.001), without
any differences of urea clearance (Figure 2). Twelve weeks
after application of ADR, SHR had developed uraemia
(Table 1) concomitant with decreased urinary urea con-
centration (SH12 versus ADR12: 939.84 ± 50.60 versus
Table 1. Body weight and biochemical parameters in experimental groups
SH6 (n = 15) ADR6 (n = 15) ADR+LOS6 (n = 9) SH12 (n = 9) ADR12 (n = 7) ADR+LOS12 (n = 10)
Body weight (g) 197.33 ± 1.82 190.33 ± 2.86 192.22 ± 4.09 205 ± 2.04# 186.43 ± 3.57§§§ 205.5±2.41#,∗∗∗
Plasma creatinine (µmol/l) 62.4 ± 2.26 61.8 ± 3.92 52.38 ± 5.07 55.78 ± 3.76 60.71 ± 4.87 62.3 ± 2.09
Plasma urea (mmol/l) 9.87 ± 0.45 7.77 ± 0.43§ 9.09 ± 0.62 8.86 ± 0.50 10.09 ± 0.94# 7.53 ± 0.42∗
Urine flow (µl/min/kg) 28.08 ± 2.24 48.95 ± 6.26§ 48.08 ± 7.89§ 39.64 ± 2.91## 73.08 ± 6.29§§§,# 64.401 ± 5.28§§
Water reabsorption (%) 99.17 ± 0.06 98.74 ± 0.10 98.94 ± 0.24 99.06 ± 0.10 98.15 ± 0.24§§,# 98.52 ± 0.14§
§P < 0.05, §§P < 0.01 and §§§P < 0.001 versus the control group; ∗P < 0.05 and ∗∗∗P < 0.001 versus the ADR group; #P < 0.05, ##P < 0.01, the
difference between two examined time points (6 and 12 weeks) in the same group.
Table 2. Arterial blood pressure in experimental groups
SH6 (n = 11) ADR6 (n = 11) ADR+LOS6 (n = 10) SH12 (n = 9) ADR12 (n = 8) ADR+LOS12 (n = 10)
SAP (mmHg) 211.09 ± 10.41 207.27 ± 6.67 175.40 ± 8.93§,∗ 215.33 ± 11.97 193.38 ± 10.65 176.30 ± 5.58§
DAP (mmHg) 151.73 ± 6.65 157.27 ± 3.53 136.90 ± 10.44 156.89 ± 8.65 141.75 ± 10.70 141.30 ± 4.19
MAP (mmHg) 175.82 ± 7.67 177.00 ± 4.53 152.20 ± 9.29§,∗ 176.78 ± 8.81 161.88 ± 10.18 155.80 ± 3.45
§P < 0.05 versus the control group, ∗P < 0.05 versus the ADR group.
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Fig. 2. Urea clearance (Cu), creatinine clearance (Ccr) and proteinuria
in experimental groups. §P < 0.05, §§P < 0.01, §§§P < 0.001 versus the
control group; ∗P < 0.05 and ∗∗P < 0.01 versus the ADR group. #P < 0.05,
##P < 0.01, the difference between two examined time points (6 and
12 weeks) in the same group.
395.86 ± 79.81 mmol/l, P < 0.001), and therefore they
reduced urea clearance drastically (Figure 2). However,
losartan completely prevented the development of uraemia
in long-term study and improved urea clearance (Table 1,
Figure 2). In accordance with pronounced elevation in the
urine flow in SH12, urea clearance was significantly in-
creased compared to values obtained in same group after
6 weeks.
ADR in a cumulative dosage of 4 mg/kg induced massive
proteinuria, as shown in Figure 2 (SH6: 0.13 ± 0.02 versus
ADR6: 1.88 ± 0.28 mg/min/kg, P < 0.001 and SH6: 0.13 ±
0.02 versus ADRLOS6: 1.13 ± 0.22 mg/min/kg, P < 0.01;
SH12: 0.05 ± 0.01 versus ADR12: 2.14 ± 0.18 and SH12:
0.05 ± 0.01 versus ADRLOS12: 1.50 ± 0.20 mg/min/kg,
P < 0.001). Both short- and long-term losartan applications
successfully reduced ADR-induced proteinuria (ADRLOS6
versus ADR6 P < 0.05, and ADRLOS12 versus ADR12
P < 0.01).
Water reabsorption, as a marker of functional state of
tubules, declined significantly in advanced ADR nephropa-
thy (Table 1).
Histological studies
Morphological changes in the kidney of all examined SHR
are shown in Table 3 and Figures 3 and 4. Histological ex-
aminations of kidney specimens obtained 6 and 12 weeks
after the second injection of ADR demonstrated significant
increase in the HP score compared to respective controls
(SH6, SH12). Short treatment with the AT-1 receptor antag-
onist losartan (ADR+LOS6) shows tendency to decrease
the HP score in relation to the ADR6 group, while long-
term losartan treatment results in significant reduction of
morphological changes compared to the ADR12 group.
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Table 3. Index of morphological changes of the kidney in experimental groups
SH6 (n = 9) ADR6 (n = 7) ADR+LOS6 (n = 8) SH12 (n = 9) ADR12 (n = 7) ADR+LOS12 (n = 10)
Presence of scars 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.00 ± 0.00 0.50 ± 0.27 0.00 ± 0.00∗
Sclerotic glomeruli 0.44 ± 0.18 1.86 ± 0.14§§§ 1.00 ± 0.19§,∗∗ 0.22 ± 0.15 3.00 ± 0.00§§§,### 2.10 ± 0.28§§§,∗∗,##
Tubular dilatation 0.00 ± 0.00 1.86 ± 0.26§§§ 1.50 ± 0.19§§§ 0.00 ± 0.00 2.57 ± 0.28§§§ 1.10 ± 0.10§§§,∗∗∗
Tubular atrophy 0.00 ± 0.00 0.29 ± 0.18 0.38 ± 0.18 0.00 ± 0.00 2.71 ± 0.27§§§,### 1.00 ± 0.00§§§,∗∗∗,##
Vascular changes 1.00 ± 0.29 1.86 ± 0.14§ 1.63 ± 0.18 1.67 ± 0.17 2.14 ± 0.13 1.70 ± 0.15
Interstitial fibrosis 0.00 ± 0.00 0.29 ± 0.18 0.38 ± 0.18 0.00 ± 0.00 2.57 ± 0.28§§§,### 1.00 ± 0.00§§§,∗∗∗,##
Infiltration 0.00 ± 0.00 1.00 ± 0.31§§§ 0.50 ± 0.19 0.00 ± 0.00 3.00 ± 0.00§§§,## 1.40 ± 0.16§§§,∗∗∗,##
HP score 1.44 ± 0.44 7.14 ± 0.67§§§ 5.38 ± 0.84§§§ 1.89 ± 0.26 15.86 ± 1.06§§§,### 8.30 ± 0.47§§§,∗∗∗,##
§P < 0.05 and §§§P < 0.001 versus the control group. ∗P < 0.05, ∗∗P <0.01 and ∗∗∗P < 0.001 versus the ADR group. ##P < 0.01, ###P < 0.001, the
difference between two examined time points (6 and 12 weeks) in the same group.
Fig. 3. (a) Normal-shaped glomeruli and tubules. (b) Blood vessel with slight miointimal hyperplasion, control group SH6 (PAS; ×400). (c) Sclerotic
glomerulus with capsular adhesion of glomerular tuff and the presence of foamy content, and focal interstitial mononuclear infiltration. (d) Blood
vessel with slight miointimal proliferation and foamy transformed vacuoles. Mild tubular dilatation with PAS positive casts, ADR6 group (PAS; ×400).






/ndt/article/24/4/1142/1890900 by Belgrade U
niversity user on 27 M
arch 2021
Losartan in hypertension with adriamycin nephropathy 1147
Fig. 4. (a) Normal-shaped glomeruli and tubules. (b) Blood vessel with mild miointimal proliferation and foamy transformed vacuoles and focal
perivascular mononuclear interstitial infiltration, control group SH12 (PAS; ×400). (c) Left glomeruli with thickening of the GBM, capsular adhesion
of glomerular tuff and the presence of foamy content in sclerotic glomerulus, global sclerosis of the right glomeruli, periglomerular interstitial fibrosis
and discrete interstitial mononuclear infiltration, tubular atrophy and dilatation with PAS positive casts. (d) Narrowing of arteriolar lumen with
extensive miointimal proliferation and light foam vacuolization of media, perivascular mononuclear interstitial infiltration, ADR12 group (PAS; ×400).
(e) Well-preserved glomerulus and tubules. (f) Blood vessel with slight mioelastofibrosis, ADR+LOS12 group (PAS; ×400).
morphological changes in all rats that received ADR was
higher than that observed 6 weeks after ADR application.
SHR revealed normal glomerular and tubular structures,
demonstrated in Figures 3a and 4a, and indexes of these
changes were shown in Table 3. FSGS with capsular adhe-
sion and foamy transformed glomerular cells were present
in both ADR groups (Figures 3c and 4c). Similar degree
of tubular dilatation was found in both, ADR6 and ADR12
groups, while tubular atrophy with protein casts was mainly
seen in advanced ADR nephropathy (ADR12). Focal inter-
stitial mononuclear infiltration was also present in early as
well as in the late phase of ADR nephropathy where it was
more intensive. The appearance of glomerular basement
membrane thickening, extensive tubular atrophy and di-
latation, as well as periglomerular interstitial inflammation
and fibrosis, were also connected to the advanced stage
of ADR-induced injury. Losartan-treated groups showed
less prominent glomerulosclerosis (ADR+LOS6 versus
ADR6, P < 0.01; ADR+LOS12 versus ADR12, P <
0.01) independent of treatment duration, since prolonged
treatment mostly prevent interstitial fibrosis, tubular at-
rophy and dilatation, as well as infiltration of mononu-
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Figures 3b and 4b represent the blood vessel with a
slight miointimal hyperplasia characteristic for hyperten-
sive states of SHR. Vascular changes, characterized by
miointimal proliferation, arterial and arteriolar wall thick-
ening with reduced lumina, and foamy transformations in
the intimae and the media were significantly increased in
ADR6 (P < 0.05) and ADR12 (P = 0.055) groups com-
pared to relevant controls (Table 3, Figures 3d and 4d).
Losartan could preserve the vascular structure, and there-
fore the morphological changes were almost similar to the
controls (Figures 3f and 4f).
Discussion
Previous studies from our laboratory showed that ACEI
captopril ameliorated glomerular and interstitial changes
but had insignificant effects on renal disease progression in
SHR with ADR nephropathy [12,15]. Our following study
with α-, β-blocker, carvedilol and carvedilol–captopril com-
bination (in the same experimental design) pointed out
beneficial effects of carvedilol on renal haemodynamics.
Carvedilol alone or in combination with captopril was able
to reduce tubulointerstitial changes but glomerulosclerosis
and progression of renal failure remained unaffected [16].
The treatment also failed to reduce proteinuria significantly
[16].
On the other hand, the data from the present study clearly
show that losartan reduces proteinuria in both early and late
stage of ADR nephropathy associated with hypertension.
This resulted in the prevention of glomerular sclerosis in
both stages and protection of tubulointerstitial damage in
the late phase of ADR nephropathy.
Proteinuria, as an important factor for the progression of
FSGS to end-stage renal disease, persisted in our model in
both early and late phases of ADR nephropathy. Hall and
coauthors [17] found notable renal dysfunction in rats after
single injection of ADR followed by 13 weeks’ captopril
treatment, without slowing down the progression of renal
insufficiency. Despite the decrease in the glomeruloscle-
rotic index, Irwin et al. [18] were also unable to prevent
proteinuria and to improve GFR by an ACEI, enalapril,
in Sprague-Dawley rats with ADR nephropathy induced
in the same way as in our experiment. However, our re-
sults from the present study demonstrate that oral admin-
istration of AT-1 receptor antagonist, losartan, in a dose of
10 mg/kg/day resulted in significant reduction of protein-
uria at both examined time points. This antiproteinuric ef-
fect was in accordance with amelioration of renal lesions,
although no difference in MAP was found between exam-
ined groups at the late stage of ADR nephropathy. Results
obtained from proteinuric patients with IgA nephropathy
treated with enalapril or irbesartan indicate that there is no
correlation between antihypertensive effects of the drugs
and changes in glomerular haemodynamics and urinary
protein excretion. In the rat model of diabetic nephropathy,
characterized by segmental glomerulosclerosis, increased
interstitial volume and progressive proteinuria, Tufescu
et al. [19] showed that both exercise and losartan could have
renal protective effects, directly influencing glomerular
cells through the mechanism independent of their haemody-
namic effects. This mechanism is probably due to glomeru-
lar macrophage infiltration, and glomerular mesangial acti-
vation and loss of podocyte foot processes. The results and
findings from our study with blockade of AT-1 receptors
further support the hypothesis that antiproteinuric effect of
the ANG II antagonist is non-haemodynamic. It seems that
its activity at the glomerular capillary wall depends on the
amelioration of the capillary permselectivity in addition to
its beneficial effects on the cell level [20].
The effects of hypertension on renal disease progres-
sion were examined in many experimental models as well
as in humans. In control SHR and in SHR treated with
ADR, in our study, hypertension is a characteristic of the
used rat strain [21], in spite of the fact that ADR may in-
duce hypertension in non-hypertensive rats. After the first
6 weeks of the experiment, the beneficial effect of losartan
on renal disease progression was due to its antihyperten-
sive action. In the long-term study, both a decrease in blood
pressure (with increase in RBF and consecutive reduc-
tion in RVR) and losartan-specific effects on preglomerular
and postglomerular arterioles could account for the decline
of glomerular capillary pressure and therefore increase of
membrane permselectivity.
Here, GFR was evaluated by urea and creatinine clear-
ance. At the early stage of ADR nephropathy, 6-week-long
losartan treatment completely repaired GFR estimated by
creatinine clearance. This renoprotective effect of the treat-
ment was partly related to the blood pressure decrease.
However, marked uraemia noticed between 6th and 12th
week of the experiment was successfully repressed by long-
term losartan treatment as a result of improved GFR mea-
sured by urea clearance, irrespective to abundant diure-
sis induced by ADR in the early and advanced FSGS.
In contrast to that, 12 weeks of losartan treatment failed
to improve creatinine clearance. There is evidence indi-
cating that measuring GFR by creatinine clearance might
be inadequate, especially under conditions associated with
uraemia [22]. Namely, the increase of creatinine release
in CRF is a consequence of its tubular excretion rather
than glomerular filtration [23]. Since the net effect of
ANG II on renal function is a combination of AT-1 and
AT-2 receptor-mediated events, with generally predominant
AT-1 receptor-mediated effects [24], AT-1 blockade induced
by losartan results in net renal vasodilatation and increased
glomerular filtration. These effects are modulated, however,
through the AT-2 receptor by activation of the autocrine cas-
cade that includes bradykinin, nitric oxide and cyclic GMP
[24].
ADR induces the decline in body-weight gain by reduc-
ing food intake and inhibiting protein synthesis [25], which
is in accordance with our findings in SHR with uraemia and
proteinuria induced by ADR. Significant decrease of body
weight in SHR 12 weeks after ADR application was ob-
tained by Herman [26] and also in the model of bilateral or
unilateral ADR-induced proteinuria in Wistar rats [27,28],
but not in Lewis rats [27]. Thus, the potential differences
regarding body-weight changes in rats treated with ADR
might be dose and strain dependent.
Tubulointerstitial injuries are usually present in protein-
uric nephropathies, irrespective of their primary cause,
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directly or indirectly contribute to tubular and interstitial
damage [29]. Calculating water reabsorption as an indicator
of tubular function, we pointed out that ADR induced heavy
proteinuria and ran into enhanced fluid leaking and reduced
water reabsorption in the late stage of ADR nephropathy.
Losartan has no effects on tubular water reabsorption in the
long-term study because of its diuretic action. However,
it prevents the development of tubulointerstitial changes
and inflammation by diminishing ultrafiltration of proteins
into tubulointerstitium, and thereby partly attenuates cellu-
lar events responsible for the lesions and decline of tubular
function.
Our results from morphological examination also sup-
port the assumption that non-haemodynamic mechanisms
are more important in slowing down the rate of renal disease
progression. In the 6-week study, analysis of renal tissue
specimens of SHR that received ADR (cumulative dosage
of 4 mg/kg b.w.) confirmed FSGS by the presence of char-
acteristic glomerular lesions and incipient tubulointerstitial
changes. However, in the 12-week study, ADR induces more
pronounced glomerular sclerotic lesions accompanied with
tubular atrophy and interstitial fibrosis. Our results clearly
showed that both short- and long-term AT-1 receptor an-
tagonist administration could prevent glomerular segmen-
tal and/or global sclerosis. Even more, long-term AT-1 re-
ceptor blockade could diminish tubulointerstitial changes
such as tubular atrophy, interstitial inflammation and
fibrosis.
In conclusion, the short-term study revealed that AT-1
receptor antagonist losartan significantly reduces the pro-
gression of ADR nephropathy. We found that losartan,
in addition to its antihypertensive effect, could improve
GFR and ameliorate glomerulosclerosis resulting in de-
creased proteinuria and therefore delayed progression of
ADR nephropathy. Moreover, prolonged treatment with
losartan, besides its beneficial role on renal haemodynam-
ics, could induce further reduction of glomerulosclerosis
associated with reduced progression of tubular atrophy and
interstitial fibrosis, thus preventing heavy proteinuria and
CRF. Taken together, the present results obtained in hy-
pertensive rats with ADR nephropathy confirmed the im-
portant role of ANG II AT-1-mediated non-haemodynamic
actions in progression of CRF.
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Anti-proteinase 3 antibodies both stimulate and prime human
neutrophils
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Abstract
Background. Anti-neutrophil cytoplasmic antibodies
(ANCA) against proteinase 3 (PR3) are postulated to injure
vascular endothelium by inducing cytokine-primed neu-
trophils to release proteolytic enzymes and generate reac-
tive oxygen species. Anti-PR3 induce exocytosis, and since
priming is associated with upregulation of plasma mem-
brane proteins by exocytosis of intracellular granules, we
tested the hypothesis that anti-PR3 prime neutrophils in the
absence of cytokines.
Methods. Isolated human neutrophils were incubated with
or without anti-PR3. Superoxide release was determined by
measuring the reduction of ferricytochrome C. Exocytosis
of secretory vesicles and specific granules was determined
by measuring the expression of CD35 and CD66b, respec-
tively, using flow cytometry.
Results. Anti-PR3 (15 µg/mL) directly stimulated superox-
ide production and enhanced FMLP-stimulated superoxide
production. Anti-PR3 (0.5 µg/mL) did not stimulate super-
oxide production but did enhance FMLP-stimulated super-
oxide production. Incubation of neutrophils with anti-PR3
resulted in time-dependent exocytosis of secretory vesicles
and specific granules. Anti-PR3-induced exocytosis, but
not superoxide production, was dependent on p38 mitogen-
activated protein kinase.
Conclusions. These data demonstrate that anti-PR3 can di-
rectly stimulate production of reactive oxygen species by
neutrophils without cytokine priming, and that anti-PR3
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ease Program, University of Louisville, 615 S. Preston Street, Louisville,
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E-mail: richard.ward@louisville.edu
prime neutrophils for increased FMLP-stimulated reactive
oxygen species production. Anti-PR3 also induce exocy-
tosis via a mechanism separate from their effect on re-
active oxygen species production. These findings suggest
that anti-PR3 ANCA may activate neutrophils and cause en-
dothelial cell injury by multiple pathways, including some
that are independent of priming by a second agent.
Keywords: ANCA; exocytosis; neutrophil; priming;
reactive oxygen species
Introduction
Anti-neutrophil cytoplasmic antibodies (ANCA) medi-
ate small vessel injury associated with a group of dis-
eases, including Wegener’s granulomatosis, microscopic
polyangiitis, renal-limited vasculitis and Churg–Strauss
syndrome. ANCA are directed against proteinase 3 (PR3)
and myeloperoxidase (MPO), and are postulated to exert
their pathogenic effect by binding to those proteins on the
surface of neutrophils, interacting with FcγRs and activat-
ing the cells. Activated neutrophils are thought to adhere
to vascular endothelial cells and induce injury through ei-
ther production of reactive oxygen species or release of
proteolytic enzymes stored in neutrophil granules.
While the role of ANCA in vascular injury is well es-
tablished, the mechanisms through which ANCA activate
neutrophils remain poorly defined. The most commonly in-
voked mechanism involves interaction of ANCA with target
antigens on the surface of neutrophils primed by cytokines,
such as tumor necrosis factor α (TNFα). Priming increases
plasma membrane expression of ANCA target antigens
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